Mimoun Azzouz

Director of GTIMC • University of Sheffield

Professor Mimoun Azzouz obtained a Master in Neuroscience with 1st Class Honours from the University of Marseille in 1994. In 1997 he was awarded a PhD in Neuropharmacology at the University Louis Pasteur in Strasbourg. He then worked as a post-doctoral scientist at the Gene Therapy Center in Lausanne, Switzerland.

He was recruited in 2000 by Oxford BioMedica as Senior Scientist, then appointed as Director of Neurobiology in 2003. In 2006, he was invited to join the University of Sheffield and was appointed to the Chair of Translational Neuroscience. Professor Azzouz is currently Deputy Head of Department for Research & Innovation.

He is a member of several Panels and Boards for various funding bodies and has won prestigious awards including the ERC Advanced Investigator (2011) and ERC Proof-of-Concept (2017) Awards. Professor Azzouz has been recently named as Board member of the British Society for Gene and Cell Therapy.

The Gene Therapy Innovation and Manufacturing Centre (GTIMC) is one of three national gene therapy innovation hubs funded by LifeArc and the Medical Research Council (MRC). Located at the University of Sheffield, the GTIMC will enable new gene therapies to benefit patients more quickly. The state-of-the-art centre brings together academic institutions, NHS trusts, non-profit and industry partners across the north of England, Midlands and Wales enabling academic-led clinical trials of novel gene therapies. The centre will utilise highly efficient processes to manufacture clinical grade adeno-associated viruses (AAV) and provide all the necessary quality assurance, regulatory certification and governance for human trials.


Also speaking

Laura Herbst

Research Fellow • Fraunhofer IPT

Joanna Norman

Senior Staff Scientist VGT • FUJIFILM Diosynth Biotechnologies

Troels Jordansen

CEO • GlycoStem

Event Info


Agenda at a Glance

Check out the Agenda at a Glance for Advanced Therapies Europe 2023.

2022 Post-Event Report

Download the post-event report for Advanced Therapies Europe 2022.